Dr John Heymach on Angiogenesis Inhibition in Lung Cancer and COVID-19 at MD Anderson

15:34
 
Share
 

Manage episode 271844746 series 2787983
By Research To Practice. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

Dr John Heymach from the MD Anderson Cancer Center discusses the role of anti-angiogenic agents in NSCLC and the status of clinical research for and treatment of lung cancer at MD Anderson during the COVID-19 pandemic.

RTP Lung Cancer Summit: https://www.researchtopractice.com/LungCancerSummit20/

Additional Resources

  • Calabro L et al. Challenges in lung cancer therapy during the COVID-19 pandemic. Lancet Respir Med 2020;8(6):542-4. Abstract
  • Dingemans AC et al. Treatment guidance for patients with lung cancer during the coronavirus 2019 pandemic. J Thorac Oncol 2020;15(7):1119-36. Abstract
  • Di Noia V et al. Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: The spark that ignites the fire? Lung Cancer 2020;145:208-10. Abstract
  • Singh AP et al. Management of lung cancer during the COVID-19 pandemic. JCO Oncol Pract 2020:OP2000286. Abstract
  • Zhao Z et al. Recommendations of individualized medical treatment and common adverse events management for lung cancer patients during the outbreak of COVID-19 epidemic. Thorac Cancer 2020;11(6):1752-7. Abstract

48 episodes